≥99% PURITY GUARANTEED•THIRD-PARTY TESTED•SAME-DAY SHIPPING USA•FREE SHIPPING $200+•
Menu
≥99% Purity
Same-Day Ship
COA Included
CJC-1295 No DAC - 5 mg
Growth Hormone Peptides

CJC-1295 No DAC

GHRH analog (Modified GRF 1-29) that stimulates natural, pulsatile growth-hormone release.

$45.00
98.9% Purity Verified

Third-Party Tested by Verum Analytics

Batch: BIL-CJCND-01-2603Mar 7, 2026
+99% Purity
Third-Party Tested
COA Available
15 sold in the last 24 hours
Order in 0h 0min for same-day shipping
Buy More, Save More
QuantityPrice
Add 2 more for 15% off
$45.00
Albert - Chief Researcher

Albert's Verdict

Without the DAC modification, CJC-1295 delivers a sharper, more physiological pituitary pulse — the half-life stays closer to endogenous GHRH patterns. Useful when research design calls for pulse rather than sustained elevation.

View COA

✓ In stock - Ships same day

Arrives as lyophilized (powder) form

Shipped freeze-dried for maximum stability and shelf life. See laboratory preparation guide for handling instructions.

Secure Checkout256-bit SSL
99%+ PurityThird-Party Verified
Same-Day ShippingOrder by 2PM EST
Satisfaction Guarantee

Product Description

CJC-1295 without DAC — also known as Modified GRF (1-29) — is a synthetic analog of growth-hormone releasing hormone (GHRH). It stimulates pulsatile GH release from the pituitary that closely mimics the body's own natural GH pattern, without desensitizing the receptor over time.

A cornerstone of GH-optimization research, CJC-1295 (No DAC) is most often paired with a GHRP such as Ipamorelin for a synergistic pulse. Studied for body composition, lean-mass preservation, recovery, sleep quality, and anti-aging applications. For research use only. Not for human or veterinary consumption.

Technical Specifications

Molecular Formula
C152H252N44O42
Molecular Weight
3367.97 g/mol
Sequence
Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2

Customer Reviews

Verified research purchases

5.0(7 reviews)
Matt S.Verified
1 week ago

My go-to source now

After trying a few different suppliers, I've settled on BioInfinity. The quality and service are consistently excellent. Highly recommend.

45 people found this helpful
Chris N.Verified
2 weeks ago

Verifiable quality

The ability to verify the COA on the testing lab's website is huge. This transparency sets BioInfinity apart from other suppliers.

52 people found this helpful
Nicole T.Verified
1 month ago

Reliable and trustworthy

I needed a reliable source with good documentation. BioInfinity delivered on all fronts. Will definitely order again.

38 people found this helpful
Susan M.Verified
3 weeks ago

Great customer service

Had questions about reconstitution and storage. The support team responded quickly with helpful answers. Great experience.

27 people found this helpful
Tony K.Verified
6 weeks ago

Bulk discounts are great

The quantity discounts make this more affordable than other options. Quality is top notch and shipping is fast. Win-win.

41 people found this helpful
Eric W.Verified
2 months ago

Quality you can trust

The COAs and third-party testing documentation give me confidence. This is what professional suppliers should look like.

58 people found this helpful
Diana L.Verified
4 weeks ago

Best value around

When you factor in quality, documentation, and service, BioInfinity offers the best value. I've tried others - this is my standard now.

33 people found this helpful

Frequently Researched Together

Commonly studied alongside in laboratory settings

Bundle total (3 items):$107.00

Research FAQ — CJC-1295 No DAC

Frequently asked questions about this compound for laboratory researchers.

What is CJC-1295 No DAC and how is it different from CJC-1295 DAC?+
CJC-1295 No DAC (also referred to as Mod GRF 1-29) is a short-acting GHRH analog studied for pulsatile GH-release research. Published literature differentiates it from the DAC variant, which carries a Drug Affinity Complex extending serum half-life into days.
Cited: PMID 16384879, PMID 22148949
What is the reported half-life of CJC-1295 No DAC?+
Published pharmacokinetic data describe CJC-1295 No DAC as having a short serum half-life — commonly cited at approximately 30 minutes — supporting research models of pulsatile GHRH stimulation.
Cited: PMID 22148949
Is CJC-1295 No DAC frequently studied alongside Ipamorelin in research?+
Research literature describes CJC-1295 No DAC and Ipamorelin in combined-protocol studies because they target complementary pathways — GHRH-receptor agonism and ghrelin/GHS-R agonism respectively. See our /buy/cjc-1295-ipamorelin product for the pre-blended research vial.
How should CJC-1295 No DAC be stored?+
Lyophilized vials store at −20 °C protected from light. Reconstituted with bacteriostatic water, store at 2–8 °C and use within 30 days. Refer to your COA.

Published research references

Peer-reviewed literature relevant to CJC-1295 No DAC research. Linked PubMed IDs open the original source.

  1. [1]Sustained-release GH releasing factor (CJC-1295) for hormone studies — J Clin Endocrinol Metab (2006) · PMID 16384879
  2. [2]Effects of CJC-1295 in human GH-deficient adults — J Clin Endocrinol Metab (2006) · PMID 16352683
  3. [3]GHRH analogs and growth hormone pulsatility — Endocr Rev (2012) · PMID 22148949
BL
Reviewed by the BioInfinity Research Team
Content reviewed by our research and quality team — biochemistry-degreed reviewers working alongside our analytical lab partner (Janoshik Analytical). Every product page is cross-checked against the cited peer-reviewed literature and the current batch's third-party COA.
For laboratory research use only. Not for human or veterinary use. Content is informational and does not constitute medical advice.

Verified reviews — CJC-1295 No DAC

1 verified buyer

★★★★★
4.0 / 5
James K.Verified buyer
Jun 11, 2026
★★★★★
research is going well

My guinea pig has lost a lot of belly fat

Reviews are submitted by verified buyers via per-order tokenized links. Reviews are evaluated for product-focused content; any review containing therapeutic claims (cured, treats, healed, etc.) may be edited or hidden to maintain compliance with FDA and platform guidelines.

Learn More About This Peptide

Browse All Peptide Research →Research Guides & Protocols

Research Use Only: This product is intended for laboratory research purposes only. Not for human consumption.

Research summary

CJC-1295 without DAC (Mod GRF 1-29) — clinical & mechanistic profile

Mod GRF 1-29 is a tetrasubstituted GHRH analog (Ala2, Gln8, Ala15, Leu27) with ~30-minute half-life (vs ~7 min native GHRH) due to DPP-IV resistance. Lacking DAC's albumin binding, it produces acute pulsatile GH release mimicking physiology, synergizing with GHRPs via complementary cAMP/Ca2+ pathways.

Research status

preclinical

Molecular weight

3367.95 g/mol

Molecular formula

C152H252N44O42

Studied applications

  • •Preserved pulsatility: ~30 min half-life produces discrete GH spikes mimicking physiological patterns
  • •DPP-IV resistance: Ala2 substitution blocks primary degradation enzyme, extending duration from ~7 to ~30 min
  • •GHRP synergy: cAMP pathway (GHRH) + Ca2+/IP3 pathway (GHRPs) produce amplified GH pulses beyond additive effects
  • •Flexible protocols: short duration allows timing with natural GH windows (sleep, exercise)
  • •No albumin binding: lacks DAC moiety, enabling rapid clearance and pulsatile administration

Mechanisms of action

  • •GHRHR full agonism: binds pituitary GHRH receptor, triggering Gs-protein coupling and adenylyl cyclase
  • •cAMP/PKA pathway: adenylyl cyclase → cAMP → PKA activation → GH gene transcription and vesicle release
  • •DPP-IV resistance: Ala2 substitution blocks dipeptidyl peptidase IV cleavage site
  • •Synergistic signaling: complements GHRP Ca2+/IP3 pathway for amplified somatotroph activation
  • •Dose-dependent peaks: produces sharp GH spikes 15-60 min post-injection, baseline by 180 min
Research constraints & safety notes
  • •Not approved for human therapeutic use
  • •Short half-life requires 2-3 daily injections for meaningful effects
  • •No completed human clinical trials for this specific compound
  • •Quality and purity of research compounds varies
  • •Optimal dosing and timing protocols not established

Peer-reviewed references

  1. CJC-1295 pharmacokinetic studies (2006)PMID: 16352683View
  2. GHRH analogs and pituitary functionPMID: 2699646View
  3. Wikipedia — CJC-1295 structure and modifications
  4. Paragon Sports Medicine — Mod GRF 1-29 mechanism review
Read the full CJC-1295 without DAC (Mod GRF 1-29) research page View public COA library

For research use only. This summary is a research-scientific overview compiled from peer-reviewed sources. It is not medical advice and is not intended for human or veterinary consumption.